What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. One analyst has rated the stock with a sell rating, nine have issued a ...

Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

The market expects 10x Genomics (TXG) to deliver a year-over ... but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

The funding environment uncertainty clouds the 2025 view, but at $12 per share, 10x Genomics has “quite a few challenges baked into the stock” price, says the analyst. However, it is “fair ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it ...

Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with ...